Lactobacillus brevis as Next Generation Probiotics
With over 10 years of live biotherapeutic product (LBP) development experience, Creative Biolabs prides itself on being an innovator and problem solver in the LBP industry. Our experienced R&D team provides you with all the support you need during the development of your products that are in the pipeline.
Introduction of Lactobacillus brevis (L. brevis)
L. brevis is a heterofermentative Gram-positive organism isolated from milk, cheese, sauerkraut, sourdough, silage, cow manure, faeces, mouth, and intestinal tract of humans and rats. L. brevis is a microaerophilic, obligately heterofermentative lactic acid bacterium, which has been reported to lack phosphotransferase systems specific for glucose, fructose, and lactose. L. brevis will not grow in media with pentose as the sole source of fermentable sugars. Identification of L. brevis strains by carbohydrate fermentation reactions or other simple phenotypic tests has proved inadequate. As a member of the genus Lactobacillus and due to its long-term use in various traditionally fermented food products, L. brevis has the GRAS status. It can be used as a potential probiotic.
L. brevis for Disease Treatment
There is increasing evidence that the use of probiotics is a promising intervention for the treatment of inflammatory diseases of a variety of microbiological etiologies. Mice treated with L. brevis CD2 or placebo were subjected to wire ligation around the maxillary second molars and placed between the gums and buccal mucosa near the ligated teeth to induce periodontitis. Mice topically treated with L. brevis CD2 displayed significantly decreased bone loss and lower expression of TNF, IL-1β, IL-6, and IL-17A as compared to placebo-treated mice. In addition, L. brevis CD2-treated mice showed a lower number of anaerobic bacteria but a higher number of aerobic bacteria than placebo treated mice. The data suggest that this probiotic preparation could have therapeutic potential in human periodontitis, possibly through both anti-inflammatory and antimicrobial effects.
Fig.1 L. brevis CD2 inhibits mRNA expression of proinflammatory cytokines. (Maekawa, 2014)
The colitic mice were prepared by rectal injection of TNBS. L. brevis G-101 showed the strongest activity in inducing IL-10 expression in LPS-stimulated peritoneal macrophages among 200 strains of lactic acid bacteria tested. However, it significantly inhibited the expression of TNF-a, IL-1β and IL-6 and the phosphorylation of IRAK1 and AKT, and activated NF-kB and MAPKs. TNBS treatment caused colon shortening, myeloperoxidase activity and the expression of IL-1β, IL-6, and TNF-α are increased in mice. Oral administration of L. brevis G-101 significantly inhibited these activities. Thus, L. brevis G-101 may be able to improve colitis.
What Services Can We Provide for L. brevis at Creative Biolabs?
L. brevis Related Products at Creative Biolabs
We supply a variety of L. brevis strains of different preservation numbers as follow. If you need other strains, please contact us.
-
Customized strain culture supernatant. (e.g.: for animal research)
-
Customized strain lyophilized powder containing certain CFU. (e.g.: for animal research)
As one of the largest LBP related services and products suppliers, Creative Biolabs has expertise and capabilities in providing high-quality solutions. You can rely on our know-how, understanding, experience, and passion for providing the best quality LBP services, in a reliable manner with quick turnaround times and the utmost respect for customer confidentiality. Please contact us for further discussion of L. brevis related products or services.
References
-
Maekawa, T.; Hajishengallis, G. Topical treatment with probiotic Lactobacillus brevis CD 2 inhibits experimental periodontal inflammation and bone loss. Journal of periodontal research. 2014, 49(6): 785-791.
For Research Use Only. Not intended for use in food manufacturing or medical procedures (diagnostics or therapeutics). Do Not Use in Humans.
Related Services
